Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Documenti analoghi

• Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
  di: Sakai, Hitomi, et al.
  Pubblicazione: (2017)
• EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib
  di: Ma, Lei, et al.
  Pubblicazione: (2019)
• Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
  di: Peng, MuYun, et al.
  Pubblicazione: (2020)
• The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR
  di: Tatematsu, Tsutomu, et al.
  Pubblicazione: (2017)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  di: Su, Kang-Yi, et al.
  Pubblicazione: (2018)